menu
    • menu
    [{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Raziel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Spaulding Clinical, LLC","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Spaulding Clinical, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Spaulding Clinical, LLC \/ Spaulding Clinical, LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Spaulding Clinical, LLC

    Menu

    Spaulding Clinical, LLC

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYN-020

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Theriva Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered ...

                            Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 16, 2021

                            Lead Product(s) : SYN-020

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Theriva Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYN-020

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Theriva Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Safety, and Tolerability of SYN-020

                            Details : SYN-020 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Radiation Enteritis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 25, 2021

                            Lead Product(s) : SYN-020

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Theriva Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bemotrizinol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study

                            Details : Bemotrizinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 21, 2020

                            Lead Product(s) : Bemotrizinol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZL-012

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Recipient : Raziel Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers

                            Details : RZL-012 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 31, 2017

                            Lead Product(s) : RZL-012

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Recipient : Raziel Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Aptinyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

                            Details : NYX-2925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 15, 2016

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Aptinyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Spaulding Clinical, LLC

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

                            Details : SB204 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2015

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Novan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth